Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 202.85 as compared to the previous close of Rs. 190.90. The total number of shares traded during the day was 107897 in over 1239 trades.

The stock hit an intraday high of Rs. 203.95 and intraday low of 191.05. The net turnover during the day was Rs. 21655437.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem UKMHRA MarketingAuthorization Baclofen10mg Tablets